Skip to content
  • Follow Us On LinkedIn
ClearNote®HealthLogo_rgb
  • Virtuoso Epigenomics Platform
  • Publications & Abstracts
  • Case Studies
  • Contact Us
A0D810F7-A9ED-4958-9395-E9A5FE421C3C
  • Virtuoso Epigenomics Platform
  • Publications & Abstracts
  • Case Studies
  • Contact Us

Day: July 7, 2023

Understanding The Limitations of CA19-9 As A Biomarker for Pancreatic Cancer Testing

Avantect pancreatic cancer test technology

Among the tools available for pancreatic cancer testing, the biomarker CA19-9 has gained attention for its potential role in monitoring and diagnosis of the disease. In this blog post, we’ll explore what CA19-9 is, how it is used in pancreatic cancer testing, and its limitations as a biomarker. 

ClearNote Health logo in white

© 2024 ClearNote Health. All rights reserved.
Avantect is a trademark of ClearNote Health. Other trademarks are the property of their respective owner.

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Virtuoso Epigenomics Platform
  • Publications & Abstracts
  • Case Studies
  • Contact Us
  • Virtuoso Epigenomics Platform
  • Publications & Abstracts
  • Case Studies
  • Contact Us